Viant, Mark R. http://orcid.org/0000-0001-5898-4119
Amstalden, E.
Athersuch, T.
Bouhifd, M.
Camuzeaux, S.
Crizer, D. M.
Driemert, P.
Ebbels, T.
Ekman, D.
Flick, B.
Giri, V.
Gómez-Romero, M.
Haake, V.
Herold, M.
Kende, A.
Lai, F.
Leonards, P. E. G.
Lim, P. P.
Lloyd, G. R.
Mosley, J.
Namini, C.
Rice, J. R.
Romano, S.
Sands, C.
Smith, M. J.
Sobanski, T.
Southam, A. D.
Swindale, L.
van Ravenzwaay, B.
Walk, T.
Weber, R. J. M.
Zickgraf, F. M.
Kamp, H.
Funding for this research was provided by:
European Chemical Industry Council (LRI-C8)
Medical Research Foundation (MR/M009157/1, MR/S010483/1)
NIHR BioResource (MC_PC_12025)
Article History
Received: 30 November 2023
Accepted: 15 January 2024
First Online: 18 February 2024
Declarations
:
: Prof. Mark Viant is an employee of the University of Birmingham and Founder and Director of Michabo Health Science Limited, a spin-out company of the University of Birmingham providing scientific consultancy services in ‘omics technologies and computational toxicology. Dr Peter Driemert, Dr Volker Haake, Dr Michael Herold, Prof. Hennicke Kamp and Dr Tilmann Walk are employees of BASF Metabolome Solutions GmbH, a company which conducts metabolome analysis for various clients. Dr Franziska Zickgraf and Dr Varun Giri are employees of BASF SE, a company which conducts and uses metabolomics studies to assess the toxicity and/or justify grouping and read-across of chemicals for the purpose of registration and marketing. The other authors have no competing interests to declare that are relevant to the content of this article.
: All procedures involving animals were conducted by BASF SE according to the German Animal Welfare legislation in an AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) certified laboratory.